NCT06821152

Functional Performance and Acceptability Evaluation of the Miss Liberty Female Condom Compared to the FC2 Female Condom

A Functional Performance and Acceptability Evaluation of the Miss Liberty Female Condom Compared to the FC2 Female Condom

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 235 (actual)
• Sponsor: University of Witwatersrand, South Africa · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate the functional performance and acceptability of the Miss Liberty female condom version 1 (Miss Liberty female condom), compared to the FC2 female condom. The study will be a sequential randomised 2-period cross-over trial comparing five uses of the Miss Liberty female condom, compared to the control FC2 female condom. Each woman will be asked to use five Miss Liberty female condoms, and five FC2 control female condoms in a randomised order. Woman will complete a Condom Use Report after each condom use. Function, safety, and acceptability will be assessed at each of two follow-up visits conducted after using each set of five condoms. The trial will enrol 235 women between 18-45 years old. The primary objective is to ascertain the functional performance of the Miss Liberty female condom compared to the control FC2 female condom. The secondary objectives are to determine the acceptability and safety (as determined by the number of adverse events) for the Miss Liberty female condom compared to the FC2 female condom.

Detailed description

The purpose of the study is to evaluate the functional performance and acceptability of the Miss Liberty female condom version 1 (Miss Liberty female condom), compared to the FC2 female condom. This research study will be a two-period, cross-over randomized controlled trial to compare the functional performance, safety and acceptability of two female condom types. Enrolled women will be asked to use five FC2, or five Miss Liberty female condoms in each study period provided to them in random order according to one of two possible sequences of each condom type. A Condom Use report will be completed after each condom use and a Condom Acceptability Questionnaire will be completed at the end of each study period after use of each set of five study condoms. If a woman expresses interest in participating, she will be given the study information sheet to read, which will describe the study requirements including her role in the study. If she agrees to take part in the research, she will be invited to the Wits MRU Commercial City site and asked to provide written informed consent. A physical examination will be undertaken to exclude visible symptoms of sexually transmitted infection. If symptoms are observed the participant will be referred to a Department of Health clinic or their doctor for treatment. A urine pregnancy test will be conducted at screening to exclude pregnancy. Woman will need to provide a copy of HIV testing results which are not older than two months. If HIV testing results are not available, voluntary HIV counselling and testing will be offered and conducted by study staff. Woman will be counselled on Pre Exposure Prophylaxis (PrEP) and referred to a local facility that provides PrEP should they wish to initiate PrEP. The consent process and all checklists, condom use reports and questionnaires used in the research will be written and conducted in a language that is understandable to the participant, and all relevant documents will be translated into isiZulu. Woman will be instructed on proper condom use. After successful completion of the screening process and documentation of informed consent the woman will be formally enrolled in the study and assigned the next consecutive participant Identification Number (PID). The Baseline Questionnaire covering information on participant demographics and previous female and male condom use will be administered in private. The study staff will discuss with the woman an approximate timeframe for use of all five condoms and a suitable follow-up date will be scheduled. This date will be noted on an appointment slip. Woman will be encouraged to come back if their condoms are finished before the due date and will be given the research study contact details to call for any appointment changes. After successful completion of the screening process and documentation of informed consent the woman will be formally enrolled in the study and assigned the next consecutive PID. Participants will be asked to return for a follow-up visit after using each set of five study condoms. There will be two follow-up visits. At each of these visits study staff will review the information on the condom reports for completeness and accuracy. Data on device function and safety (individual Condom Use Reports) for each condom type will be collected during follow-up visits. Condom use instructions will be reviewed as a reminder before use of the next set of study condoms. The participation period for each study woman is expected to last between 2-3 months. During the 1st in-person follow-up visit, women will be interviewed about their first assigned condom type and they will receive their next condom packet within their second randomly assigned use sequence. In the second follow-up visit, woman will be interviewed about their second assigned condom type and will be discontinued from study participation. If the woman experiences any failure event during sexual intercourse they will be offered HIV testing and STI testing (Chlamydia/gonorrhoea). Woman will be instructed to return any unopened condoms at the next visit. If a woman does not keep their scheduled follow-up visit, research personnel will initiate a reminder contact and reschedule the visit. Each follow-up interview should be scheduled approximately one month after the preceding visit. At the second follow-up visit, woman will return their five completed Condom Use Reports for the second set of condoms. Any missing or unclear responses on the Condom Use Reports will be clarified at this time. A Condom Acceptability Questionnaire will be completed at the visit. Woman who fail to return to the site for the second follow-up visit will be contacted by research staff to reschedule the visit. Woman may discontinue from the study before the scheduled end. A woman which does not complete both study periods will be classified as an early discontinuer and classified as follows: * Medical/safety reason(e.g. the female partner becomes pregnant, or has a sensitivity/allergic reaction to the research study products, or is diagnosed with a new onset sexually transmitted infection, etc.); * Non-safety reason related to use of the research study products (e.g. she dislikes the research study products and/or fails to follow protocol requirements that are felt to significantly alter study outcomes); * Non-safety reasons NOT related to use of the research study products (e.g. desires pregnancy, moves, relationship with partner dissolved, does not wish to continue, etc.); * Loss-to-follow-up if a participating woman has not returned to the clinic for their scheduled follow-up visit and all efforts to locate them have failed. * Investigator decision The investigator decides to discontinue the woman from the study for a safety or other study related circumstance. Two hundred and thirty five eligible women willing to participate in the study will be randomized to condom use order. To minimize a potential learning effects, women will be randomly assigned to the sequence of use of condom type. Use-order assignments will be computer generated using REDCap. Women will be randomly assigned in balanced blocks of size 2, 4 or 6 chosen at random to one of two possible condom use sequences: 1. Type A - Type B 2. Type B - Type A A separate randomization process (implemented by an independent statistician) will allocate one of the two study condom types to the letters A and B which will be used to label individual packs of five condoms for distribution to study women and to record the condom type used in each study period. Study staff will be masked to the extent possible until all data have been captured and the primary analysis programs have been verified. Due to physical differences between the study products (color, texture, width) masking study participants and clinic staff can only be assured during enrolment and collection of baseline data, but cannot be maintained throughout the study. The statistician preparing the randomization sequences and analyzing the data will remain masked while developing and testing the analysis programs and procedures and drafting the preliminary study report. The date the statistician is unmasked will be documented.

Conditions

• Functional Performance

Interventions

Type	Name	Description
DEVICE	Miss Liberty Condom	The Miss Liberty female condom is manufactured by Zhejiang Rui Bo 001 High Polymer Co, Ltd. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The sheath, are made of polyurethane. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. Miss Liberty measures 180mm in length and 78mm in lay-flat width. The device is pre-lubricated with silicone oil. This condom is a similar design (material, length, width) to the USFDA approved FC1 female condom which was discontinued and replaced by FC2.
DEVICE	FC2 condom	The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark of the European Union. The FC2 is pre-qualified by the WHO. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 170mm in length and 80mm in lay-flat width. The device is pre-lubricated with silicone oil. This FC is available in the public health sector in South Africa.

Timeline

• Start date: 2025-05-21
• Primary completion: 2025-10-15
• Completion: 2025-10-15
• First posted: 2025-02-11
• Last updated: 2025-11-24

Locations

1 site across 1 country: South Africa